Safety Evaluation of Pancreatic Islet Transplantation Without Immunosuppression in Adults With Type 1 Diabetes

The primary objective of this study is to evaluate the **safety** of pancreatic islet transplantation without immune suppression in adult subjects with **type 1 diabetes**. This is clinically relevant as it aims to explore a potential treatment option that could mitigate the need for lifelong immunosuppressive therapy, which is associated with significant side effects and risks. The study does not specify any secondary objectives.

The clinical trial involves participants diagnosed with **Type 1 Diabetes**. The study population includes both male and female subjects, with an age range of 18 to 65 years. The trial population was selected to include a vulnerable population, although specific selection criteria have not been disclosed. The sponsor has not provided information regarding the total number of participants. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and any key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed to evaluate the safety of pancreatic islet transplantation without immune suppression in adult subjects diagnosed with **type 1 diabetes**. This is a first-in-human study, categorized as a Phase 1 trial, which aims to assess the initial safety profile of the intervention. The trial follows a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial is approximately 22 months, with recruitment expected to commence on November 10, 2023, and the study anticipated to conclude by September 1, 2025.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit is crucial for determining the suitability of participants for the trial. Following successful inclusion, participants will attend regular follow-up visits, which are scheduled to monitor their health status and any potential adverse effects of the treatment. These visits are integral to ensuring participant safety and collecting data on the intervention's impact. The trial will culminate in an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the trial is contingent upon the study's timeline, with individual participation lasting until the end-of-study visit unless early termination is warranted. Conditions that may lead to early termination include the occurrence of significant adverse events, withdrawal of consent by the participant, or any other medical or ethical reasons deemed necessary by the study investigators. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is November 10, 2023, with an anticipated end date of September 1, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant clinical parameters. The schedule for measuring and collecting data is typically aligned with the trial's timeline, ensuring systematic data collection at predefined intervals. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product. The trial's design and methodology adhere to regulatory standards to ensure the reliability and validity of the findings.